Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds

 
• By Jessica Merrill
  
opened yellow scissors over turquoise blue background
Biogen may have cost cuts ahead in 2021 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business